Categories: News

Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities

In accordance with its long-term incentive program (“LTIP”) Ambu A/S has allocated performance share units (PSUs) to members of the Executive Board. Reference is made to the company announcement of 29 January 2021 regarding the implementation of the program and the first allocations.

Pursuant to the Market Abuse Regulation article 19, Ambu A/S hereby notifies receipt of information of the following transactions in Ambu’s shares by persons discharging managerial responsibilities in Ambu A/S. 

1. Details of the person discharging managerial responsibilities/person closely associated
a) Name Michael Højgaard Abrahamsen
2. Reason for the notification
a) Position/status CFO
b) Initial notifica- tion/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auc-
tion monitor
a) Name Ambu A/S
b) LEI 5299008W2A69WX355710
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instru- ment

 

Identification code

Performance Share Units linked to shares in Ambu A/S

 

 

 

 

DK0060946788

b) Nature of the transaction Allocation of Performance Share Units according to Long-Term Incentive Program.
c) Price(s) and volume(s)   Price(s) Volume(s)
DKK 0 7,254 PSUs
   
   
   
   
d) Aggregated information
  • Aggregated volume
  • Price
 

N/A

 

N/A

 

e) Date of the transaction 29 January 2021
f) Place of the transaction Outside a trading venue

Attachment

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

16 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

17 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

3 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

4 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

18 hours ago